Carisma Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Carisma Therapeutics Inc (CARM) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Carisma Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 20M vs 565,111M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+806.6% annualized vs trailing 12 months), vs decelerating (-30.8%) for its tracked peer group.
- Growth: Carisma Therapeutics Inc generated 1,236.8% revenue growth year over year in Q3 2025, vs 9.0% for its tracked competitors combined.
- Profitability: Its 197.6% net margin compares with 25.0% for the peer group.
- Peer revenue share: Carisma Therapeutics Inc accounted for 0.1% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.43M compares with $0.97M for the peer group (0.4x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CARM Sales vs. its Competitors, Q3 2025
Carisma Therapeutics Inc reported revenue growth of 1,236.78 % year on year in Q3 2025, above its competitors' combined revenue growth of 9.04 %.
With a net margin of 197.64 %, Carisma Therapeutics Inc achieved higher profitability than its competitors (24.96 %).
Carisma Therapeutics Inc generated 0.05 % of the combined sales of its peer group, up from 0.00 % a year earlier.
Carisma Therapeutics Inc vs. its Competitors, Q3 2025
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Carisma Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Carisma Therapeutics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (8) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Carisma Therapeutics Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs 1,236.8% for Carisma Therapeutics Inc. Carisma Therapeutics Inc's share of combined industry revenue moved from 0.00% to 0.01%, a gain of 0.01 percentage points.
Carisma Therapeutics Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Carisma Therapeutics Inc | - | - | - | Yes |
| Competitors combined (70) | ||||
| High-Confidence Competitors (9) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CARM Stock Performance relative to its Competitors
CARM Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 2 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 3 | Rallybio Corporation | 282.9% | Outperformed |
| 4 | Nuvectis Pharma inc | 282.9% | Outperformed |
| 5 | Nurix Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Carisma Therapeutics Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Carisma Therapeutics Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Carisma Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Carisma Therapeutics Inc | 0.03 | 19.96 |
| Eli Lilly And Company | 1,058,703.83 | 79,665.80 |
| Johnson and Johnson | 652,897.56 | 97,929.00 |
| Merck and Co Inc | 368,820.40 | 66,569.00 |
| Novartis Ag | 284,863.05 | 56,674.00 |
| Astrazeneca Plc | 256,496.02 | 58,739.00 |
| SUBTOTAL | 3,319,311.11 | 594,741.74 |
Sign in to see all competitors of Carisma Therapeutics Inc .
Sources: Carisma Therapeutics Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Carisma Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Carisma Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| CG Oncology | Named by the company | 85% |
| Medical Enterprises Ltd. | Named by the company | 85% |
| Theralase Technologies Inc. | Named by the company | 85% |
| AstraZeneca | Named by the company | 85% |
| FerGene Inc. | Named by the company | 85% |
| NYU | Named by the company | 85% |
| Allogene Therapeutics Inc | Named by the company | 85% |
| Endo Pharmaceuticals Inc. | Named by the company | 85% |
| Merck & Co., Inc. | Named by the company | 85% |
| Trustees of the University of Pennsylvania | Named by the company | 85% |
| Penn | Named by the company | 85% |
| Bristol-Myers Squibb | Named by the company | 85% |
| ImmunityBio | Named by the company | 85% |
| Penn | Named by the company | 85% |
| Aadi, LLC | Named by the company | 85% |
| F. Hoffmann-La Roche AG | Named by the company | 85% |
| Moderna | Named by the company | 85% |
| Curis Inc | Named by the company | 85% |
| Apexigen Inc | Named by the company | 85% |
| Pfizer Inc | Named by the company | 85% |
| Nextcure Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Carisma Therapeutics Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Carisma Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.26 % |
| Merck and Co Inc | Pharmaceutical segment 88.88 % |
| Pfizer Inc | U.S. Commercial Division 52.92 % |
| Madrigal Pharmaceuticals Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Carisma Therapeutics Inc .
Carisma Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Carisma Therapeutics Inc | 0 | 434,000 | 1,664,370 |
| Eli Lilly And Company | 1,058,704 | 1,593,316 | 534,224 |
| Johnson and Johnson | 652,898 | 695,518 | 149,411 |
| Merck and Co Inc | 368,820 | 887,587 | 42,267 |
| Novartis Ag | 284,863 | 752,973 | 185,566 |
| Astrazeneca Plc | 256,496 | 706,847 | 123,141 |
| PEERS TOTAL | 3,319,311 | 966,455 | 146,974 |
Sign in to see all peers for Carisma Therapeutics Inc .
Carisma Therapeutics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 61.21 % |
| Johnson and Johnson | United States 57.42 % |
| Merck and Co Inc | EMEA 23.60 % |
| Gilead Sciences Inc | United States 70.78 % |
| Pfizer Inc | United States 58.91 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Carisma Therapeutics Inc .
Carisma Therapeutics Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Carisma Therapeutics Inc's industry classification, broader than the peer set above. Market cap in millions of $.Carisma Therapeutics Inc ranks #0 of 498 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 824, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,054,271 | 19.27 % |
| 2 | Johnson and Johnson | 662,243 | 12.10 % |
| 3 | Beone Medicines Ltd | 543,752 | 9.94 % |
| 4 | Abbvie Inc | 473,291 | 8.65 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Carisma Therapeutics Inc | 0 | 0.00 % |
Market cap and industry share for the rest of Carisma Therapeutics Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Carisma Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (342 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 1.2x | 25.1x | -23.9x |
| EV / EBITDA | - | 17.3x | - |
| P/B | -0.4x | 4.5x | -4.9x |
| Return on Equity | -274.80 % | industry aggregate | -292.42 % |
| Return on Invested Capital | -45.32 % | -2.95 % (avg) | -42.37 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Carisma Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - | 31.14 % |
| Operating Margin | - | - | - | - | - | - | -594.31 % | -317.58 % |
| Return on Invested Capital | -27.92 % | -2.69 % | -93.65 % | -41.54 % | -5.92 % | - | -55.22 % | -203.04 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Carisma Therapeutics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 824 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Carisma Therapeutics Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Carisma Therapeutics Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Carisma Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+806.6% annualized vs trailing 12 months).
Weaknesses
- Return on equity 292.4 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (50.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-30.8% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Carisma Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Carisma Therapeutics Inc | 0.72 | 1.13 | - |
| Eli Lilly And Company | 0.20 | 1.48 | 1.59 |
| Johnson and Johnson | 0.37 | 1.05 | 0.60 |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
Sign in to see all peers for Carisma Therapeutics Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Carisma Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Carisma Therapeutics Inc | Q3 2025 | +1,236.8 % | - |
| Eli Lilly And Company | Q2 2026 | +47.7 % | +25.3 % |
| Johnson and Johnson | Q2 2026 | +6.6 % | -0.1 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| PEERS TOTAL | +8.7 % | -21.4 % |
Sign in to see all peers for Carisma Therapeutics Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Carisma Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Carisma Therapeutics Inc | Q3 2025 | - | - |
| Eli Lilly And Company | Q2 2026 | +33.5 % | +72.8 % |
| Johnson and Johnson | Q2 2026 | +5.5 % | +26.7 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
Sign in to see all peers for Carisma Therapeutics Inc .
Carisma Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Carisma Therapeutics Inc | 528.22% | 1,948.98% | - |
| Eli Lilly And Company | 21.97% | 33.95% | 92.54% |
| Johnson and Johnson | 10.60% | 13.30% | 25.74% |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
Sign in to see all peers for Carisma Therapeutics Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Carisma Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Carisma Therapeutics Inc | 0.00 | 0.00 |
| Eli Lilly And Company | 39.77 | 13.29 |
| Johnson and Johnson | 30.97 | 6.67 |
| Merck and Co Inc | 120.42 | 5.54 |
| Novartis Ag | 20.37 | 5.03 |
| Astrazeneca Plc | 25.09 | 4.37 |
| PEERS AVERAGE | 36.67 | 5.58 |
Sign in to see all peers for Carisma Therapeutics Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.